GB2146529A - Oral dobutamine preparation - Google Patents

Oral dobutamine preparation Download PDF

Info

Publication number
GB2146529A
GB2146529A GB08423485A GB8423485A GB2146529A GB 2146529 A GB2146529 A GB 2146529A GB 08423485 A GB08423485 A GB 08423485A GB 8423485 A GB8423485 A GB 8423485A GB 2146529 A GB2146529 A GB 2146529A
Authority
GB
United Kingdom
Prior art keywords
dobutamine
preparation
active ingredient
plasma
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08423485A
Other languages
English (en)
Other versions
GB8423485D0 (en
Inventor
Junichiro Mifune
Hideo Yamada
Noboru Nagafuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of GB8423485D0 publication Critical patent/GB8423485D0/en
Publication of GB2146529A publication Critical patent/GB2146529A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB08423485A 1983-09-16 1984-09-17 Oral dobutamine preparation Withdrawn GB2146529A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58171594A JPS6061523A (ja) 1983-09-16 1983-09-16 経口用ドブタミン製剤

Publications (2)

Publication Number Publication Date
GB8423485D0 GB8423485D0 (en) 1984-10-24
GB2146529A true GB2146529A (en) 1985-04-24

Family

ID=15926052

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08423485A Withdrawn GB2146529A (en) 1983-09-16 1984-09-17 Oral dobutamine preparation

Country Status (5)

Country Link
JP (1) JPS6061523A (ja)
DE (1) DE3433678A1 (ja)
FR (1) FR2551974A1 (ja)
GB (1) GB2146529A (ja)
IT (1) IT1179127B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663351A (en) * 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
EP0476846A2 (en) * 1990-08-27 1992-03-25 Eli Lilly And Company Method for treating imflammation, ischemia-induced cell damage and muscular dystrophy
US5280046A (en) * 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
US5552439A (en) * 1990-08-27 1996-09-03 Eli Lilly And Company Method of treating inflammatory bowel disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1392674A (en) * 1972-04-12 1975-04-30 Lilly Co Eli Dopamine derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1453034A (en) * 1972-12-15 1976-10-20 Boehringer Sohn Ingelheim Pharmaceutical composition for treating spasticity
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1392674A (en) * 1972-04-12 1975-04-30 Lilly Co Eli Dopamine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTINDALE }THE EXTRA PHARMACOPOEIA}, DECEMBER 1982, THE PHARMACEUTICAL PRESS *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663351A (en) * 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
EP0476846A2 (en) * 1990-08-27 1992-03-25 Eli Lilly And Company Method for treating imflammation, ischemia-induced cell damage and muscular dystrophy
EP0476846A3 (en) * 1990-08-27 1992-08-05 Eli Lilly And Company Method for treating imflammation, ischemia-induced cell damage and muscular dystrophy
US5281623A (en) * 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
US5393786A (en) * 1990-08-27 1995-02-28 Eli Lilly And Company Method for treating inflammation, ischemia-induced cell damage and muscular dystrophy
US5552439A (en) * 1990-08-27 1996-09-03 Eli Lilly And Company Method of treating inflammatory bowel disease
US5280046A (en) * 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes

Also Published As

Publication number Publication date
DE3433678A1 (de) 1985-03-28
GB8423485D0 (en) 1984-10-24
FR2551974A1 (fr) 1985-03-22
JPS6061523A (ja) 1985-04-09
IT8467927A1 (it) 1986-03-14
IT8467927A0 (it) 1984-09-14
IT1179127B (it) 1987-09-16

Similar Documents

Publication Publication Date Title
US4556678A (en) Sustained release propranolol tablet
JP6581625B2 (ja) 代謝障害を治療するための組成物および方法
KR910004572B1 (ko) 경구용 당뇨병 치료제 제형의 제조방법
US20220370366A1 (en) Tablets containing cilofexor and pharmaceutically acceptable carriers
JP5698682B2 (ja) トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途
CN111635309A (zh) 一种新型解热镇痛药物及其制备方法和用途
TWI327469B (en) Pharmaceutical composition
CN111635315B (zh) 一种解热镇痛药物及其制备方法和用途
JPS625913A (ja) ジヒドロピリジン含有製剤
GB2146529A (en) Oral dobutamine preparation
US6441041B1 (en) (-)-hydroxycitric acid for the prevention of osteoporosis
JP2872695B2 (ja) 腎炎の治療剤
WO1996011682A1 (fr) Composition preventive et remede pour les maladies allergiques de type i
Walter-Sack et al. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals
US11013707B2 (en) Administration of oral methyldopa
Strisower et al. PHYSIOLOGIC EFFECTS OF l-TRIIODOTHYRONLNE
JP3024789B2 (ja) 血圧降下剤
US5342853A (en) Method of using nor-verapamil and nor-gallopamil as anti-arteriosclerotics
US4443469A (en) Uric acid-lowering composition, method and use
EA006776B1 (ru) Фармацевтическая композиция для лечения диабетической невропатии
WO2022144021A1 (zh) Dorzagliatin和胰高血糖素样肽-1类似物的药物组合物
JP2835547B2 (ja) 糖尿病治療剤
JPH09227371A (ja) 粥状動脈硬化抑制剤
JPH03291220A (ja) アスコクロリン誘導体を有効成分とするＣａ代謝異常改善剤
JP3066051B2 (ja) 橋本甲状腺炎治療剤

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)